Cargando…

Clinical utility of circulating cell-free DNA in advanced colorectal cancer

BACKGROUND: Circulating cell-free DNA (cfDNA) isolated from the plasma of cancer patients (pts) has been shown to reflect the genomic mutation profile of the tumor. However, physician and patient assessment of clinical utility of these assays in patients with metastatic colorectal cancer (mCRC) has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pereira, Allan A. Lima, Morelli, Maria Pia, Overman, Michael, Kee, Bryan, Fogelman, David, Vilar, Eduardo, Shureiqi, Imad, Raghav, Kanwal, Eng, Cathy, Manuel, Shanequa, Crosby, Shadarra, Wolff, Robert A., Banks, Kimberly, Lanman, Richard, Talasaz, AmirAli, Kopetz, Scott, Morris, Van
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574560/ https://www.ncbi.nlm.nih.gov/pubmed/28850629 http://dx.doi.org/10.1371/journal.pone.0183949

Ejemplares similares

FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma
por: Korphaisarn, Krittiya, et al.
Publicado: (2017)

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
por: Sarshekeh, Amir Mehrvarz, et al.
Publicado: (2017)

Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma
por: Korphaisarn, Krittiya, et al.
Publicado: (2019)

Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer
por: Davis, Jennifer S., et al.
Publicado: (2022)

Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
por: Villaflor, Victoria, et al.
Publicado: (2016)

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
por: Raghav, Kanwal, et al.
Publicado: (2016)

Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction
por: Chouhan, Jay, et al.
Publicado: (2015)

Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery
por: Uemura, Marc, et al.
Publicado: (2017)

Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
por: Johnson, Benny, et al.
Publicado: (2022)

Survival improvement for patients with metastatic colorectal cancer over twenty years
por: Zeineddine, Fadl A., et al.
Publicado: (2023)

Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin
por: Overman, Michael J., et al.
Publicado: (2016)

Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review
por: Shen, Chan, et al.
Publicado: (2022)

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
por: Schwaederle, Maria, et al.
Publicado: (2016)

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
por: Parseghian, Christine, et al.
Publicado: (2023)

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases
por: Mack, Philip C., et al.
Publicado: (2020)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
por: Serpas Higbie, Victoria, et al.
Publicado: (2022)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis
por: Kim, Seung Tae, et al.
Publicado: (2017)

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer
por: Lieu, Christopher H., et al.
Publicado: (2013)

Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer
por: Morris, Van K., et al.
Publicado: (2022)

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine
por: Overman, M J, et al.
Publicado: (2010)

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
por: Kato, Shumei, et al.
Publicado: (2019)

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
por: Lanman, Richard B., et al.
Publicado: (2015)

Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology
por: Serpas, Victoria J., et al.
Publicado: (2018)

Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma
por: Raghav, Kanwal, et al.
Publicado: (2021)

Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer
por: Raghav, Kanwal, et al.
Publicado: (2020)

Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92‐Gene Assay
por: Raghav, Kanwal, et al.
Publicado: (2020)

Underreporting of race/ethnicity in COVID-19 research
por: Raghav, Kanwal, et al.
Publicado: (2021)

Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer
por: Chen, Z-Y, et al.
Publicado: (2015)

Association between KRAS mutation and lung metastasis in advanced colorectal cancer
por: Pereira, A A L, et al.
Publicado: (2015)

Natural history and prognostic factors for localised small bowel adenocarcinoma
por: Colina, Andreina, et al.
Publicado: (2020)

The use of glucocorticoids in marmoset wasting syndrome
por: Otovic, Pete, et al.
Publicado: (2015)

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer
por: Kopetz, Scott, et al.
Publicado: (2014)

Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait
por: Huey, Ryan W., et al.
Publicado: (2019)

Cancer of Unknown Primary Presenting as Bone‐Predominant or Lymph Node‐Only Disease: A Clinicopathologic Portrait
por: Huey, Ryan W., et al.
Publicado: (2021)

The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor
por: Liu, Yi, et al.
Publicado: (2018)

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018)

Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C(max) and improved tolerability, in patients with solid tumors
por: Ajani, Jaffer A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_phphbgtmfc5n9g9s4hinkpb5a9